Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : AMGN save search
Sandoz receives FDA approval for first and only denosumab biosimilars
Published: 2024-03-05 (Crawled : 19:00) - globenewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.46%
H: 1.3%
C: 0.44%
fda first approval
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Published: 2023-12-13 (Crawled : 21:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.91%
H: 2.03%
C: 1.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: -1.78%
fda lung review cancer cell application grants advanced
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.27%
H: 0.99%
C: -0.67%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.06%
C: -1.01%
lumakras fda treatment meeting application
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Published: 2023-06-21 (Crawled : 14:20) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.8%
H: 0.36%
C: -2.33%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.8%
C: -0.5%
blincyto fda approval treat grants leukemia
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Published: 2022-10-11 (Crawled : 12:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.12%
H: 2.63%
C: 1.59%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 1.06%
H: 3.53%
C: 0.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 3.16%
H: 4.59%
C: 2.48%
bbp-398 lumakras fda designation lung pharma trial cancer fast track designation
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 7.48%
H: 0.45%
C: -4.8%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.32%
H: 0.2%
C: -1.16%
rituxan fda biosimilar
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Published: 2021-12-01 (Crawled : 21:00) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.54%
H: 3.8%
C: 2.35%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.03%
H: 2.04%
C: 0.76%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.55%
H: 0.59%
C: -1.88%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
fda
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse
Published: 2021-12-01 (Crawled : 19:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.18%
C: 0.22%
fda
FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product’s benefit
Published: 2021-07-14 (Crawled : 19:26) - fda.gov
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.15%
H: 1.33%
C: 0.94%
fda
Tezepelumab Granted Priority Review By U.S. FDA
Published: 2021-07-08 (Crawled : 07:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.71%
H: 4.93%
C: 3.36%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.42%
H: 1.01%
C: 0.02%
fda granted grant
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
Published: 2021-05-28 (Crawled : 21:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.59%
H: 0.91%
C: -0.14%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.59%
H: 0.91%
C: -0.14%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
fda lung cancer cancer fda approval diagnostic
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: 0.82%
H: 2.28%
C: -0.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
fda lung cancer therapy cancer drug fda approval approval
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.41%
H: 2.09%
C: 1.72%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
treatment fda lung cancer cancer fda approval
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
Published: 2021-05-10 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.63%
H: 0.95%
C: -2.15%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.38%
H: 0.27%
C: -0.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.7%
H: 1.1%
C: -1.32%
fda license application
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.